Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10899-10909

  Liontos, Michalis ^a   Koutsami, Marilena ^a   Sideridou, Maria ^a   Evangelou, Konstantinos ^a   Kletsas, Dimitris ^b   Levy, Brynn ^d   Kotsinas, Athanassios ^a   Nahum, Odelia ^d   Zoumpourlis, Vassilis ^c   Kouloukoussa, Mirsini ^a   Lygerou, Zoi ^e   Taraviras, Stavros ^e   Kittas, Christos ^a   Bartkova, Jirina ^f   Papavassiliou, Athanasios G ^a   Bartek, Jiri ^f   Halazonetis, Thanos D ^g   Gorgoulis, Vassilis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITY OF PATRAS   (Greece)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^g UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

REPLICATION LICENSING FACTOR CDT1; REPLICATION LICENSING FACTOR HCDC6; REPLICATION LICENSING FACTOR HCDT1; UNCLASSIFIED DRUG;

ARTICLE; BEHAVIOR; CANCER GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; DNA REPLICATION; DYSPLASIA; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NUCLEAR PROTEINS; PHENOTYPE;

EID: 36348944160     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2837     Document Type: Article

References (50)

1. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 2007;19:238-45.
2. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633-7.
3. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
4. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
5. Mailand N, Diffley JF. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 2005;122:915-26.
6. Nishitani H, Lygerou Z. Control of DNA replication licensing in a cell cycle. Genes Cells 2002;7:523-34.
7. Vaziri C, Saxena S, Jeon Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 2003;11:997-1008.
8. Tatsumi Y, Sugimoto N, Yugawa T, Narisawa-Saito M, Kiyono T, Fujita M. Deregulation of Cdt1 induces chromosomal damage without rereplication and leads to chromosomal instability. J Cell Sci 2006;19:3128-40.
9. Karakaidos P, Taraviras S, Vassiliou LV, et al. Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability - evidence of E2F-1 transcriptional control over hCdt1. Am J Pathol 2004;165:1351-65.
10. Gonzalez S, Klatt P, Delgado S, te al. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 2006;440:702-6.
11. Murphy N, Ring M, Heffron CC, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005;58:525-34.
12. Bonds L, Baker P, Gup C, Shroyer KR. Immunohistochemical localization of Cdc6 in squamous and glandular neoplasia of the uterine cervix. Arch Pathol Lab Med 2002;126:1163-8.
13. Xouri G, Lygerou Z, Nishitani H, Pachnis V, Nurse P, Taraviras S. Cdt1 and geminin are down-regulated upon cell cycle exit and are over-expressed in cancer-derived cell lines. Eur J Biochem 2004;271:3368-78.
14. Bravou V, Nishitani H, Song SY, Taraviras S, Varakis J. Expression of the licensing factors, Cdt1 and Geminin, in human colon cancer. Int J Oncol 2005;27:1511-8.
15. Gorgoulis V, Zoumpourlis V, Rassidakis G, et al. Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index. Virchows Arch 1995;426:339-44.
16. Jiang W, Wells NJ, Hunter T. Multistep regulation of DNA replication by Cdk phosphorylation of HsCdc6. Proc Natl Acad Sci U S A 1999;96:6193-8.
17. Nishitani H, Taraviras S, Lygerou Z, Nishimoto T. The human licensing factor for DNA replication Cdt1 accumulates in G1 and is destabilized after initiation of S-phase. J Biol Chem 2001;276:44905-11.
18. Koutsami MK, Tsantoulis PK, Kouloukoussa M, et al. Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression. J Pathol 2006;209:512-21.
19. Santoni-Rugiu E, Duro D, Farkas T, et al. E2F activity is essential for survival of Myc-overexpressing human cancer cells. Oncogene 2002;21:6498-509.
20. Gorgoulis VG, Zacharatos P, Mariatos G, et al. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics. Cancer Res 2001;61:538-49.
21. Al-Romaih K, Bayani J, Vorobyova J, et al. Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genet Cytogenet 2003;144:91-9.
22. Petersen BO, Lukas J, Sorensen CS, Bartek J, Helin K. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J 1999;18:396-410.
23. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer. Eur J Cancer 2005;41:2403-14.
24. Fujita M. Cdt1 revisited: complex and tight regulation during the cell cycle and consequences of deregulation in mammalian cells. Cell Div2006;17:22.
25. O'Keefe LV, Richards RI. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett 2006;232:37-47.
26. Levy B, Hirschhorn K. Protocols and Applications (Methods in Molecular Biology). In: Fan Y-S, editor. Molecular Cytogenetics. Humana Press; 2002. p. 121.
27. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998;1378:F21-59.
28. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-5.
29. DiTullio RA, Jr., Mochan TA, Venere M, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002;4:998-1002.
30. Lew DJ, Kornbluth S. Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 1996;8:795-804.
31. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
32. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006;444:638-42.
33. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev2000;14:2015-27.
34. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000;406:207-10.
35. Dellaire G, Ching RW, Ahmed K, et al. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol 2006;175:55-66.
36. Bøe SO, Haave M, Jul-Larsen A, Grudic A, Bjerkvig R, Lønning PE. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. J Cell Sci 2006;119:3284-95.
37. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
38. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725-30.
39. Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2002;2:815-25.
40. Fenech M. Cytokinesis-block micronucleus assay evolves into a "cytome" assay of chromosomal instability, mitotic dysfunction and cell death. Mutat Res 2006;600:58-66.
41. Abulaiti A, Fikaris AJ, Tsygankova OM, Meinkoth JL. Ras induces chromosome instability and abrogation of the DNA damage response. Cancer Res 2006;66:10505-12.
42. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825-37.
43. Illidge TM, Cragg MS, Fringes B, Olive P, Erenpreisa JA. Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. Cell Biol Int 2000;24:621-33.
44. Popescu NC. Genetic alterations in cancer as a result of breakage at fragile sites. Cancer Lett 2003;192:1-17.
45. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell 2002;111:779-89.
46. Malmanche N, Maia A, Sunkel CE. The spindle assembly checkpoint: preventing chromosome mis-segregation during mitosis and meiosis. FEBS Lett 2006;580:2888-95.
47. Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006;17:295-304.
48. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
49. Zoumpourlis V, Solakidi S, Papathoma A, Papaevangeliou D. Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. Carcinogenesis 2003;24:1159-65.
50. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-81.